h Whether targeted or universal decolonization strategies for the control of methicillin-resistant Staphylococcus aureus (MRSA) select for resistance to decolonizing agents is unresolved. The REDUCE-MRSA trial (ClinicalTrials registration no. NCT00980980) provided an opportunity to investigate this question. REDUCE-MRSA was a 3-arm, cluster-randomized trial of either screening and isolation without decolonization, targeted decolonization with chlorhexidine and mupirocin, or universal decolonization without screening to prevent MRSA infection in intensive-care unit (ICU) patients. Isolates from the baseline and intervention periods were collected and tested for susceptibility to chlorhexidine gluconate (CHG) by microtiter dilution; mupirocin susceptibility was tested by Etest. The presence of the qacA or qacB gene was determined by PCR and DNA sequence analysis. A total of 3,173 isolates were analyzed; 2 were nonsusceptible to CHG (MICs, 8 g/ ml), and 5/814 (0.6%) carried qacA or qacB. At baseline, 7.1% of MRSA isolates expressed low-level mupirocin resistance, and 7.5% expressed high-level mupirocin resistance. In a mixed-effects generalized logistic regression model, the odds of mupirocin resistance among clinical MRSA isolates or MRSA isolates acquired in an ICU in intervention versus baseline periods did not differ across arms, although estimates were imprecise due to small numbers. Reduced susceptibility to chlorhexidine and carriage of qacA or qacB were rare among MRSA isolates in the REDUCE-MRSA trial. The odds of mupirocin resistance were no different in the intervention versus baseline periods across arms, but the confidence limits were broad, and the results should be interpreted with caution.
H
ealth care-associated infections due to methicillin-resistant Staphylococcus aureus (MRSA) are associated with high attributable mortality, increased length of stay, and excess cost (1) . Colonization with MRSA typically precedes infection and plays a major role in its dissemination in hospitals (2) . Both targeted decolonization (i.e., decolonization of patients who are identified as carrying MRSA) and universal decolonization (i.e., decolonization of populations of hospital patients regardless of MRSA colonization status) have been demonstrated to decrease cross-transmission and infection (3, 4) .
The anterior nares are the primary reservoir for MRSA in humans, and the application of topical nasal mupirocin is a common decolonization strategy (5) . Mupirocin interferes with bacterial protein synthesis by competitive inhibition of bacterial isoleucyl-tRNA-synthetase (6) . High-level mupirocin resistance (HLMR) is conferred by the mupA or mupB gene, both of which encode novel isoleucyl-tRNA-synthetases (6) . These genes are carried on plasmids, enabling their spread. Low-level mupirocin resistance (LLMR) results from mutations in the native chromosomal isoleucyl-tRNA-synthetase gene; these mutations are typically stable and nontransferable (7) . HLMR has been associated with decolonization failure (8) , while LLMR may predispose to early recolonization (9) . Prolonged and widespread use of mupirocin for decolonization has been associated frequently, but not universally, with the development of mupirocin resistance (10, 12) .
Antiseptic bathing of patients, most commonly with chlorhexidine gluconate (CHG), is another evidence-based approach to MRSA decolonization; antiseptic baths are often employed together with nasal mupirocin (4, 13, 14) . CHG kills by binding covalently to the bacterial cell membrane, resulting in depolarization and cell death. CHG susceptibility testing methods and breakpoints have not been standardized. Broth microdilution, which was developed to predict the activity of systemic antibiotics, is the susceptibility testing method reported most frequently, despite questions about its relevance for predicting the activity of a topical biocide such as CHG (15) . Reduced susceptibility to CHG in MRSA occurs via efflux, and identification of plasmid-mediated genes, such as qacA and qacB, that encode multidrug efflux pumps has been considered genotypic evidence of CHG nonsusceptibility by some (16, 17) . However, the relationship between the carriage of multidrug efflux pump genes and decreased susceptibility to CHG is inconsistent; phenotypic susceptibility has been demonstrated in MRSA strains that carry qacA or qacB, and reduced susceptibility has been reported in strains that lack these or other multidrug efflux pump genes (15, (18) (19) (20) . The inconsistency may be due in part to the ability of the pump encoded by qacA, but not that encoded by qacB, to utilize CHG as a substrate. Despite this important functional difference, qacA and qacB are closely related genetically and are difficult to differentiate without DNA sequence analysis; most publications do not distinguish between the two genes.
The relationship between reduced CHG susceptibility and clinical resistance in MRSA is even more tenuous. CHG has been used widely in health care for more than 50 years, and reduced susceptibility as measured by in vitro methods has been reported across the globe (18, (20) (21) (22) (23) (24) 46 ), yet decolonization failure related to nonsusceptibility has been described only rarely (16, 25, 26) . Of note, topical concentrations of CHG used for decolonization remain Ͼ200-fold higher than the highest CHG MICs and minimum bactericidal concentrations (MBCs) recorded for staphylococci (15, 25) .
The Randomized Evaluation of Decolonization versus Universal Clearance to Eradicate MRSA (REDUCE-MRSA) trial (ClinicalTrials registration no. NCT00980980) was a clusterrandomized, multicenter study designed to compare three MRSA control strategies: (i) screening and isolation, (ii) screening, isolation, and targeted decolonization with mupirocin and CHG, and (iii) universal decolonization with CHG and mupirocin without screening (27) . Universal decolonization with CHG and mupirocin was found to be superior to both alternative strategies in reducing MRSA infections. In order to evaluate the effect of decolonization on the susceptibility of MRSA to CHG and mupirocin, we conducted a secondary analysis of isolates collected during the baseline and intervention periods from all three study arms and subjected them to phenotypic and genotypic susceptibility testing. (27) . In this pragmatic clinical trial, 43 Hospital Corporation of America (HCA)-affiliated hospitals in 16 states were assigned at random to one of three MRSA prevention strategies, with all adult ICUs in a given hospital assigned to the same strategy. Arm 1 employed admission screening for MRSA and isolation of patients who were found to be colonized or infected; arm 2, targeted decolonization (i.e., admission screening, isolation, and decolonization of patients who were colonized or infected with MRSA with a 5-day regimen of twice-daily intranasal mupirocin ointment and daily CHG baths); and arm 3, universal decolonization (i.e., no screening; decolonization of all patients with 5 days of twice-daily intranasal mupirocin ointment and daily CHG baths for the entire ICU stay).
During the trial, microbiology laboratories at each participating hospital were instructed to collect the first clinical or anterior-nares screening isolate of MRSA per ICU patient. If both a clinical isolate and a surveillance isolate were available, the clinical isolate was preferred. MRSA isolates were shipped to a central laboratory at Rush University Medical Center (RUMC) for confirmation of MRSA status and further testing. Isolates were excluded if they were not MRSA or if they could not be verified to have been collected from a patient during or after an ICU stay during a study period. Additionally, in arm 3, because screening for MRSA was to have been discontinued during the intervention period, isolates collected from screening cultures were excluded. Clinical isolates were considered to have been acquired during an ICU stay (to be "ICU attributable") if they were collected between 3 days after ICU admission and 2 days after ICU discharge.
All isolates were tested for susceptibility to CHG and mupirocin. A sample of 15 isolates per hospital per study period, as well as any isolate with a CHG MIC of Ͼ4 g/ml, was tested further for the presence of qacA and qacB. Baseline period isolates were selected at random. During the intervention period, the isolates with the latest culture dates were preferred, in order to enrich for isolates with the greatest potential exposure to the intervention. If fewer than 15 isolates were available, all isolates were tested.
Clinical and demographic data were extracted from HCA electronic corporate data warehouses. This study was reviewed and approved by the Harvard Pilgrim Health Care Institutional Review Board (IRB), the central institutional review board for the trial (reference number 367981), and by the IRB of RUMC. Written informed consent was waived (27) . (29) . Isolates that tested susceptible to methicillin underwent mecA PCR (30); mecA-positive isolates were classified as MRSA.
(ii) CHG and mupirocin susceptibility testing. CHG susceptibility testing was performed using broth microdilution and a complete inhibition endpoint (47) . Starting with a 20% (wt/vol) CHG solution (SigmaAldrich, St. Louis, MO), a 2-fold dilution series (from 32 to 0.0625 g/ml) was prepared daily. An isolate was classified as nonsusceptible to CHG if the MIC was Ͼ4 g/ml, which is outside the wild-type distribution of CHG MICs for S. aureus (epidemiologic cutoff) (31, 48) . Susceptibility to mupirocin was determined by the Etest method (bioMérieux, Durham, NC) according to the manufacturer's instructions. LLMR was defined as a MIC of 8 to 256 g/ml and HLMR as a MIC of Ն512 g/ml (6). When MICs were compared between groups, a 4-fold difference was considered significant (32) . MBCs of CHG were determined in triplicate for all qacAor qacB-positive isolates and for isolates with CHG MICs of Ͼ4 g/ml (33).
(iii) PCR for qacA and qacB. A real-time PCR assay was developed and was used to identify qacA and qacB (see the Supplemental Data and Table  S1 in the supplemental material) (34) . Isolates were tested after overnight growth on tryptic soy agar with 25 g/ml ethidium bromide (SigmaAldrich), which was added to provide selective pressure for strains that harbored efflux pumps such as those encoded by qacA and qacB (35) . S. aureus SK2355 (qacA), S. aureus SK2725 (qacB) (gifts from Arnold Bayer [36] ), and S. aureus NRS123 (qac negative [37] ) were included as control strains in every run.
(iv) DNA sequence analysis of qacA and qacB amplicons. To distinguish between qacA and qacB, a conventional PCR primer pair was designed to amplify a 1,423-bp region internal to both genes (Supplemental Data and Table S1 ). pCR-BluntII-TOPO vector (Invitrogen, Carlsbad, CA)-cloned products were sequenced bidirectionally (ACGT Inc., Wheeling, IL). Sequences were compared to canonical qacA and qacB reference sequences (GenBank accession no. GU565967.1 and AF053772.1).
(v) MLST. All isolates positive for qacA or qacB underwent multilocus sequence typing (MLST). The protocol, including allelic number and sequence type (ST) assignment methods, is available at the S. aureus MLST database (http://saureus.mlst.net/). Statistical analysis. Because this was a secondary analysis, the sample size was not calculated. Demographic and clinical characteristics were compared between arms with generalized linear mixed models that accounted for within-hospital clustering. A generalized logistic mixed-effects regression model was used to estimate the effects of the trial on mupirocin resistance. Generalized logistic regression resembles logistic regression except that it simultaneously estimates the odds ratios (OR) for both low-and high-level resistance relative to no resistance. Mixed effects were used to account for randomization by cluster (38) . Because hospitals did not submit every MRSA isolate they collected, we used multiple imputation to generate estimated effects that incorporated the isolates with unknown susceptibility patterns (39) (40) (41) . Trial effects were assessed by a 4-degree-of-freedom difference-in-differences test of the interaction, comparing the difference in the odds ratio for each level of resistance, for the baseline versus the intervention period, across arms. Analyses were performed using SAS proc glimmix software, version 9.3 (SAS Institute).
RESULTS

Characteristics of MRSA isolates and patients.
A total of 7,405 eligible MRSA isolates were identified by local laboratories during the baseline and intervention periods; 4,566 isolates were sent to the central laboratory. Of these, 1,393 were excluded, leaving 3,173 (43%) isolates for analysis (Fig. 1) .
Most isolates were collected from the anterior nares of patients on the first day of hospitalization (Table 1) . On average, patients from whom MRSA was isolated were elderly and had multiple comorbid conditions. Isolate or population descriptors were similar among the three arms during both the baseline and the intervention periods. Collection site and hospital day of specimen collection differed in arm 3 during the intervention period, when surveillance cultures for MRSA were discontinued (Table 1) .
CHG susceptibility. CHG MICs for all MRSA isolates collected during the baseline period displayed a narrow, unimodal distribution that did not change significantly during the intervention period (Fig. 2) . The CHG MIC 50 and MIC 90 were 2 g/ml and 4 g/ml, respectively, for both the baseline and intervention periods. There were no significant differences in MIC distributions or in the MIC 50 or MIC 90 when isolates were stratified by arm or when only the clinical isolates acquired in an ICU were analyzed (data not shown). Two clinical MRSA isolates (both identified in arm 1, intervention period) were nonsusceptible to CHG (MIC, 8 g/ml) and carried qacA (see Table 3 ). For the subset of non-CHG-susceptible or qacA-or qacB-positive isolates tested, MBCs were never more than 4-fold higher than MICs, indicating that the isolates were not tolerant to CHG (see Table 3 ) (33).
Mupirocin susceptibility. Among all MRSA isolates collected during the baseline period (n ϭ 735), 7.1% expressed LLMR (range, 5.9% in arm 2 to 8.1% in arm 1) and 7.5% expressed HLMR (range, 5.0% in arm 1 to 11% in arm 3) with no significant differences in prevalence among arms. Because arm 3 did not collect surveillance cultures during the intervention period, we restricted further analyses to clinical isolates. Using imputed values for the number of mupirocin-resistant isolates, we did not find a significant difference-in-differences in the proportion of LLMR or HLMR isolates between baseline and intervention periods across arms for all clinical isolates or for clinical isolates attributable to an ICU stay ( Table 2 .) The small number of clinical isolates attributable to an ICU stay (Fig. 1 ) resulted in extremely wide confidence intervals (CI) for these comparisons (Table 2) .
qacA, qacB, and MLST. We tested 411 baseline isolates and 403 intervention isolates for qacA and qacB by PCR. Five MRSA isolates (0.6%) were found to carry qac genes: 4 carried qacA, and 1 carried qacB (Table 3) . One isolate was collected during the baseline period (arm 1), and 4 isolates were collected during the intervention period (3 in arm 1 and one in arm 3). Isolates were submitted from 5 different hospitals; 4 isolates were submitted from hospitals located in Florida.
We identified three different S. aureus sequence types by MLST, including a novel sequence type (ST2484) characterized by a tpi allele that had not been described previously (Table 3 ). The novel sequence type was submitted to the MLST website curator and was approved. All other isolates belonged to clonal complex 8, a lineage of MRSA identified commonly in the United States (42) .
DISCUSSION
In a large sample of MRSA isolates collected during the REDUCE-MRSA trial, decreased susceptibility to CHG, as measured by CHG MICs and carriage of qacA or qacB, was rare and was similar in frequency among MRSA isolates identified in decolonization arms and in the screening and isolation arm. The prevalence of mupirocin resistance at baseline was moderate (7.1% LLMR and 7.5% HLMR), and the odds of mupirocin resistance during the intervention versus the baseline period did not differ between the targeted or universal decolonization arms, on the one hand, and the screening and isolation arm, on the other. One theoretical explanation for our findings is that the success of decolonization applied diligently in all ICUs of a hospital reduced the prevalence of MRSA sufficiently to prevent the selection of resistance. The generalizability of our findings is strengthened by the large number of isolates tested and their broad geographic distribution across 16 states. The low prevalence of nonsusceptibility to CHG in the population is striking. Two of 3,173 isolates tested nonsusceptible to CHG (MIC, 8 g/ml), and 5 of 814 isolates were found to carry qacA or qacB. Only one of these isolates was identified in a decolonization arm, suggesting that CHG nonsusceptibility and qacA or qacB carriage were independent of exposure to decolonization.
The optimum susceptibility testing method and breakpoints for CHG and S. aureus are not defined. We used protocols endorsed by the Clinical and Laboratory Standards Institute that are widely accepted as reference methods for categorizing bacterial susceptibility to antibiotics and that have been used often in other studies of staphylococcal susceptibility to CHG, allowing our results to be compared to those in published reports. The susceptibility breakpoint for CHG applied in this study was derived from the MIC epidemiologic cutoff, a standard approach used when validated breakpoints are not available (31, 48) . As in other reports (15, 19, 20) , qacA was not a specific predictor of CHG resistance: three of five qacA-positive isolates were susceptible to CHG, and MBCs were always within 2 doubling dilutions of MICs. Of note are two isolates that carried qacA and expressed LLMR; the combination of LLMR and qacA carriage was a risk factor for decolonization failure in one case-control study (16) .
Our results are consistent with several other published surveys that infrequently identified phenotypic or genotypic evidence of reduced susceptibility to CHG in MRSA isolates from U.S. health care facilities (22, 23, 35) . More recently, reports have emerged of (49) . These reports, together with the few descriptions of decolonization failure associated with reduced CHG susceptibility (16, 25, 26) , justify surveillance for CHG resistance during sustained decolonization programs that employ routine CHG bathing. While our inability to detect increases in CHG or mupirocin resistance in the decolonization arms of this trial is encouraging, our study has limitations. First, most of the MRSA isolates available for investigation were identified in cultures collected from patients on the first day of hospital admission; these patients would have had little exposure to CHG or mupirocin during targeted or universal decolonization interventions. While some patients may have undergone decolonization during an earlier ICU stay, readmissions to study ICUs were not tallied, so information about prior exposure to decolonization is unknown. Second, isolates were not selected randomly but instead comprised a convenience sample. We may have reduced the risk of sampling bias by testing isolates in a central laboratory and delaying the release of results to participating hospitals until after the trial closed. Third, the intervention period was relatively short (18 months), and results may not be generalizable to longer periods of routine decolonization. Fourth, we looked for only two efflux pump genes; other efflux pumps that can use CHG as a substrate have been described in S. aureus (18, 35) .
Some limitations of our study apply specifically to the detection of mupirocin resistance. Most notably, few ICU-attributable isolates were available for analysis, resulting in imprecise estimates of odds ratios for a difference-in-differences in the prevalence of mupirocin resistance during the intervention versus the baseline period, across arms. Other investigators have reported increases in both LLMR and HLMR associated with increases in mupirocin use in hospitals (43, 44) ; exposure to mupirocin was an independent risk factor for colonization with mupirocin-resistant MRSA in a case-control study of general inpatients in one hospital (45) . The risk of the development of mupirocin resistance appears to be greatest when mupirocin use is widespread and sustained over long periods, and when it is applied to extranasal anatomic sites, such as vascular catheter exit sites and wounds (4, 6) . Whether the application of mupirocin to the anterior nares of all ICU patients will eventually select for mupirocin resistance and reduce the effectiveness of the universal decolonization strategy could not be determined by our analysis, but the issue remains a concern and should be monitored.
In summary, CHG nonsusceptibility and carriage of qacA or qacB were rare in a large sample of MRSA isolates from the REDUCE-MRSA trial. We did not detect an increase in the odds of mupirocin resistance in the intervention versus the baseline period, but confidence limits were broad, and our results should be interpreted with caution. Health care facilities that use CHG and mupirocin for targeted or universal decolonization should monitor S. aureus isolates for resistance to these agents.
